EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mosquito Saliva Subunit Vaccine Enhances Efficacy of VLP Vaccines Against Zika and Chikungunya Viruses

Siân Jossi, Megan Cole iD, Yonca Keskek Turk iD, Sam Verwimp iD, Katrien Trappeniers, James Luk, Joshua X D Ang, Luke Alphey, Leen Delang iD, Clive S McKimmie iD, Olga Pleguezuelos iD

Vaccines · 21.08.2026 · 14 (8) · 723

DOI: 10.3390/vaccines14080723 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 21.08.2026. Verfasst von Siân Jossi und 10 weiteren Autor:innen. Beteiligte Einrichtung: ConserV Bioscience Ltd., Heyford Park Innovation Centre, Upper Heyford, Bicester OX25 5HD, UK. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation - Flanders, Wellcome Trust, Innovate UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Mosquito-borne viruses cause substantial global morbidity and mortality. Mosquito saliva, secreted during biting, facilitates blood feeding and can enhance virus infection. Here, we evaluated whether combining virus-specific antigens with mosquito salivary protein-derived peptides improves protection in Zika virus (ZIKV) and chikungunya virus (CHIKV) mouse models.

Methods

Peptides from Aedes and Culex salivary proteins were selected based on conservation, predicted T-cell reactivity, and cellular and humoral immunogenicity in mice. Mice were immunised subcutaneously with a prime and boost two weeks apart using adjuvanted salivary peptides (SAL), commercial ZIKV- or CHIKV-like particles (VLPs), or salivary peptides combined with the relevant VLPs. Vaccine doses contained 0.5 µg VLPs and/or 10 nmol of each salivary peptide, formulated with Montanide ISA-51; when combined, VLPs and SAL were administered on opposite flanks. Two weeks after boosting, mice were challenged with ZIKV or CHIKV plus Aedes aegypti saliva. Challenge teams were blinded to group allocation until data analyses were complete.

Results

SAL enhanced the protective effect of VLP vaccination compared with VLPs alone. In the CHIKV model, CHIKV VLP + SAL prevented joint swelling and reduced infectious virus in the inoculated ankle and viral RNA in the contralateral ankle. In the ZIKV model, ZIKV VLP + SAL reduced viral RNA in skin and brain tissue and improved survival.

Conclusions

Mosquito salivary peptide antigens improved the protective efficacy of VLP vaccines against ZIKV and CHIKV in mouse models. Salivary antigens may provide a complementary vaccine component for multiple arboviruses transmitted by Aedes and Culex mosquitoes.

Schlagwörter

Stichwörter der Autor:innen

AedesCulexT-cellVLPsZikaantibodiesarboviruschikungunyamosquito salivapeptidesvaccine

Autor:innen und Institutionen

  • ConserV Bioscience Ltd., Heyford Park Innovation Centre, Upper Heyford, Bicester OX25 5HD, UK.
  • Virus Host Interaction Team, Skin Research Centre, Hull York Medical School, University of York, York YO10 5DD, UK.
  • Laboratory of Virus-Host Interactions and Therapeutic Applications, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belg…
  • Department of Biology, University of York, York YO10 5DD, UK.
  • York Biomedical Research Institute, University of York, York YO10 5DD, UK.

ORCID-Profile: Megan Cole, Yonca Keskek Turk, Sam Verwimp, Leen Delang, Clive S McKimmie, Olga Pleguezuelos

Förderung

  • Research Foundation - Flanders
  • Wellcome Trust
  • Innovate UK
  • Biotechnology and Biological Sciences Research Council
  • DHSC
  • BBSRC
  • Research Foundation Flanders PhD fellowship

Zitieren

APA

Jossi, S., Cole, M., Keskek Turk, Y., Verwimp, S., Trappeniers, K., Luk, J., Ang, J. X. D., Alphey, L., Delang, L., McKimmie, C. S., & Pleguezuelos, O. (2026). Mosquito Saliva Subunit Vaccine Enhances Efficacy of VLP Vaccines Against Zika and Chikungunya Viruses. Vaccines, 14(8), 723. https://doi.org/10.3390/vaccines14080723

Vancouver

Jossi S, Cole M, Keskek Turk Y, Verwimp S, Trappeniers K, Luk J, et al. Mosquito Saliva Subunit Vaccine Enhances Efficacy of VLP Vaccines Against Zika and Chikungunya Viruses. Vaccines. 2026;14(8):723. doi:10.3390/vaccines14080723

BibTeX
@article{Jossi2026,
  author = {Jossi, Siân and Cole, Megan and Keskek Turk, Yonca and Verwimp, Sam and Trappeniers, Katrien and Luk, James and Ang, Joshua X D and Alphey, Luke and Delang, Leen and McKimmie, Clive S and Pleguezuelos, Olga},
  title = {Mosquito Saliva Subunit Vaccine Enhances Efficacy of VLP Vaccines Against Zika and Chikungunya Viruses},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {723},
  doi = {10.3390/vaccines14080723}
}
Kostenlos starten →